



## Nathaniel Myall

Clinical Assistant Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Medicine**

300 Pasteur Dr Rm JC007

Stanford, CA 94305

Tel (650) 725-5071      Fax (650) 725-5849

### Bio

---

### CLINICAL FOCUS

- Lung Cancer
- Neuroendocrine Tumors
- Medical Oncology

### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

### ADMINISTRATIVE APPOINTMENTS

- Medical Director, Inpatient Med 11 Service, (2024- present)

### HONORS AND AWARDS

- Humanism in Hematology/Oncology Award, Division of Oncology, Stanford Hospital and Clinics (2019)
- Methods in Clinical Cancer Research Workshop, ASCO/AACR (2019)
- Charles Dorsey Armstrong Award for Excellence in Patient Care by a Senior Resident, Department of Internal Medicine, Stanford Hospital and Clinics (2015)

### PROFESSIONAL EDUCATION

- Board Certification, Hematology, American Board of Internal Medicine (2019)
- Board Certification, Oncology, American Board of Internal Medicine (2019)
- Board Certification, Internal Medicine, American Board of Internal Medicine (2015)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2019) CA
- Residency, Stanford University, Internal Medicine Residency, CA (2015)
- Medical Education: Stanford University School of Medicine (2012) CA

## Research & Scholarship

---

### CLINICAL TRIALS

- A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2, Recruiting
- Phase I/II Delayed or Upfront Brain RT in Tx Naïve Lung Cancer Patients w/ Brain Metastases, Recruiting
- Phase I Afatinib&Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance, Not Recruiting

### Publications

---

#### PUBLICATIONS

- **DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed EGFR-Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.** *JTO clinical and research reports*  
Aredo, J. V., Singhal, S., Berry, G. J., Moradi, F., Wakelee, H. A., Myall, N. J., Ramchandran, K. J., Das, M., Suarez, C. J., Neal, J. W., Riess, J. W. 2025; 6 (12): 100913
- **Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System- Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes** *JTO CLINICAL AND RESEARCH REPORTS*  
Singhal, S., Hui, C., Neal, J. W., Nagpal, S., Roy, M., Das, M., Ramchandran, K., Pollom, E., Selvaggi, G., Wakelee, H. A., Myall, N. J. 2025; 6 (12)
- **Accuracy of DOTATATE-positron emission tomography for preoperative nodal staging of carcinoid tumors of the lung.** *JTCVS open*  
Tsai, L. L., Bommakanti, S., Sridharan, S., Myall, N. J., Guenthart, B. A., Liou, D. Z., Lui, N. S., Backhus, L. M., Berry, M. F., Shrager, J. B., Elliott, I. A. 2025; 27: 157-163
- **Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*  
Sun, F., Banwait, M. K., Singhal, S., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L., Ullah, A. T., Guo, E. W., Wakelee, H. A., Neal, J. W., Das, M. S., Ramchandran, et al 2025; 208: 108747
- **Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.** *Clinical lung cancer*  
Sun, F., Nagpal, S., Singhal, S., Neal, J. W., Wakelee, H. A., Myall, N. J., Bolan, P., Riess, J. W., Gandara, D. R., Das, M. S. 2025
- **FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases.** *Translational cancer research*  
Sun, F., Neal, J. W., Myall, N. J. 2025; 14 (6): 3295-3301
- **Delayed or upfront brain radiotherapy in treatment-naïve lung cancer patients with asymptomatic or minimally symptomatic brain metastases and ALK rearrangements (DURABLE)**  
Palmer, J., Myall, N., Schenk, E. L., Abu Rous, F., Wei, L., Pilcher, C., Spahnle, B., Tobin, C., Cameron, K., Owen, D. LIPPINCOTT WILLIAMS & WILKINS.2025: TPS2090
- **Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors** *JTO CLINICAL AND RESEARCH REPORTS*  
Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., Padda, S. K. 2025; 6 (2)
- **A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.** *International journal of radiation oncology, biology, physics*  
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. v., Pratapneni, A., Le-Budka, M. L., Wong, S., Brown, E., Barnick, K., Wakelee, H. A., Das, et al 2024

- **ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals.** *Current problems in cancer*  
Myall, N. J., Das, M.  
2024; 53: 101133
- **Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Pike, L. R., Miao, E., Boe, L. A., Patil, T., Imber, B. S., Myall, N. J., Pollom, E. L., Hui, C., Qu, V., Langston, J., Chiang, V., Grant, M., Goldberg, et al  
2024: JCO2302668
- **The Impact of Tumor Size on Node Involvement in Typical Lung Carcinoids.** *Annals of thoracic surgery short reports*  
Elliott, I. A., Liou, D. Z., Lui, N. S., Backhus, L. M., Shrager, J. B., Myall, N., Berry, M. F.  
2023; 1 (4): 543-547
- **Advancements without consensus: differing practice patterns highlight unanswered questions in the management of brain metastases from EGFR- and ALK-positive non-small cell lung cancer.** *Journal of thoracic disease*  
Hui, C., Pollom, E. L., Li, G., Myall, N. J.  
2023; 15 (11): 5877-5884
- **BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC).** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*  
Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negro, et al  
2023
- **Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.** *Clinical lung cancer*  
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., Wakelee, H. A., Neal, J. W., Kovalchuk, N., Chin, A., Diehn, M., Loo, B. W., Xiang, et al  
2023
- **Personalized Accelerated ChEMoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.** *Clinical lung cancer*  
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., Ramchandran, K., Myall, N. J., Pham, D., Xing, L., Yang, Y., Kovalchuk, N., Yuan, et al  
2023
- **Advancements without consensus: differing practice patterns highlight unanswered questions in the management of brain metastases from EGFR- and ALK-positive non-small cell lung cancer** *JOURNAL OF THORACIC DISEASE*  
Hui, C., Pollom, E. L., Li, G., Myall, N. J.  
2023
- **Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.** *JAMA network open*  
Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., Stehr, H., Wood, D., Henry, S. M., Backhus, L. M., Leung, A. N., Wakelee, H. A., Han, et al  
2023; 6 (9): e2335813
- **Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.** *JACC. CardioOncology*  
Waliy, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.  
2023; 5 (1): 85-98
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*  
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al  
2022: OP2200128
- **Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer**  
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lin, J. Y., Lu, J. T., Li, G., Hayden, M., Myall, N., Soltys, et al  
ELSEVIER SCIENCE INC.2022: E54-E55
- **Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.** *Journal of neuro-oncology*

- Hui, C., Qu, V., Wang, J. Y., von Eyben, R., Chang, Y. C., Chiang, P. L., Liang, C. H., Lu, J. T., Li, G., Hayden-Gephart, M., Wakelee, H., Neal, J., Ramchandran, et al  
2022
- **Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.** *JCO precision oncology*  
Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., Henry, S., Wood, D., Stehr, H., Ji, H., Nagpal, S., Hayden Gephart, M., Wakelee, et al  
2022; 6: e2200220
  - **Simultaneous Cases of Carfilzomib-Induced Thrombotic Microangiopathy in 2 Patients With Multiple Myeloma.** *Federal practitioner : for the health care professionals of the VA, DoD, and PHS*  
Myall, N. J., Wang, S. X., Hall, E. T., Witteles, W. H., Leung, L., Dunn, T. J., Hong, W. J.  
2022; 39 (Suppl 3): S56-S62
  - **Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.** *JCO precision oncology*  
Giustini, N. P., Patel, S. P., Myall, N. J., Fernando do Prado Moura, J., Kulkarni, A., Chao, R. C., Wakelee, H., Bazhenova, L.  
2022; 6: e2100551
  - **Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.** *JCO precision oncology*  
Dankner, M., Wang, Y., Fazlzad, R., Johnson, B., Nebhan, C. A., Dagogo-Jack, I., Myall, N. J., Richtig, G., Bracht, J. W., Gerlinger, M., Shinozaki, E., Yoshino, T., Kotani, et al  
2022; 6: e2200107
  - **Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.** *Clinical lung cancer*  
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., Li, C., Pagtama, J., Tisch, A. H., Neal, J. W.  
2022
  - **Implementation and efficacy of a fellow-led, case-based noon lecture series.**  
Dickerson, J., Myall, N., Roy, M., Johnson, T.  
LIPPINCOTT WILLIAMS & WILKINS.2022
  - **Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.** *International journal of radiation oncology, biology, physics*  
No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., Neal, J., Wakelee, H., Chin, A., Diehn, M., Loo, B. W., Chang, D. T., Pollom, et al  
2022
  - **Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.** *Translational lung cancer research*  
Gu, X., Wang, W., Wu, W., Zhang, Y., Shao, L., Santarpia, M., Christopoulos, P., Myall, N. J., Shi, Z., Lou, G.  
2022; 11 (5): 902-909
  - **In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*  
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al  
1800; 17 (2): e12-e14
  - **Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies.** *Neuro-oncology advances*  
Myall, N. J., Yu, H., Soltys, S. G., Wakelee, H. A., Pollom, E.  
2021; 3 (Suppl 5): v52-v62
  - **Brain Metastases in EGFR- and ALK-positive Non-Small Cell Lung Cancer: Outcomes of CNS Penetrant Tyrosine Kinase Inhibitors (TKIs) Alone versus in Combination with Radiation.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*  
Thomas, N. J., Myall, N. J., Sun, F., Patil, T., Mushtaq, R., Yu, C., Sinha, S., Pollom, E. L., Nagpal, S., Camidge, D. R., Rusthoven, C. G., Braunstein, S. E., Wakelee, et al  
2021

- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*  
Waliyany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.  
2021
- **Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series.** *Translational lung cancer research*  
Myall, N. J., Lei, A. Q., Wakelee, H. A.  
2021; 10 (1): 487–95
- **Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.** *Clinics in chest medicine*  
Myall, N. J., Das, M.  
2020; 41 (2): 211–22
- **Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer** *LUNG CANCER*  
Horn, L., Bauml, J., Forde, P. M., Davis, K. L., Myall, N. J., Sasane, M., Dalal, A., Culver, K., Wozniak, A. J., Baik, C. S., Mutebi, A., Zhang, P., Wakelee, et al  
2019; 128: 74–90
- **Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.** *Clinical lung cancer*  
Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., Wakelee, H. A.  
2018
- **-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.** *oncologist*  
Baik, C. S., Myall, N. J., Wakelee, H. A.  
2017
- **Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer** *TRANSLATIONAL CANCER RESEARCH*  
Myall, N. J., Wakelee, H. A.  
2016; 5: S1233-S1240
- **Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.** *Clinical lung cancer*  
Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., Diehn, M., Wakelee, H. A.  
2016; 17 (2): e17-21
- **Variations in the neurobiology of reading in children and adolescents born full term and preterm** *NEUROIMAGE-CLINICAL*  
Travis, K. E., Ben-Shachar, M., Myall, N. J., Feldman, H. M.  
2016; 11: 555-565
- **Developmental Changes within White Matter Tracts of Healthy Children Age 9 to 16 Years Old**  
Yeatman, J. D., Myall, N. J., Dougherty, R. F., Wandell, B. A., Feldman, H. M.  
LIPPINCOTT WILLIAMS & WILKINS.2013: S5
- **Case series: fractional anisotropy along the trajectory of selected white matter tracts in adolescents born preterm with ventricular dilation.** *Journal of child neurology*  
Myall, N. J., Yeom, K. W., Yeatman, J. D., Gaman-Bean, S., Feldman, H. M.  
2013; 28 (6): 771-777
- **Tract Profiles of White Matter Properties: Automating Fiber-Tract Quantification** *PLOS ONE*  
Yeatman, J. D., Dougherty, R. F., Myall, N. J., Wandell, B. A., Feldman, H. M.  
2012; 7 (11)
- **G328E and G409E sialin missense mutations similarly impair transport activity, but differentially affect trafficking** *MOLECULAR GENETICS AND METABOLISM*  
Myall, N. J., Wreden, C. C., Wlizla, M., Reimer, R. J.  
2007; 92 (4): 371-374